scholarly journals Once-Weekly Administration of High-Dosage Etanercept in Patients with Plaque Psoriasis: Results of a Pilot Experience (Power Study)

2006 ◽  
Vol 19 (1) ◽  
pp. 205873920601900 ◽  
Author(s):  
N. Cassano ◽  
F. Loconsole ◽  
A. Galluccio ◽  
A. Miracapillo ◽  
M. Pezza ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Life Quality ◽  
Severity Index ◽  
Tumour Necrosis Factor Receptor ◽  
Comparable Rate ◽  
Dosing Regimens ◽  
Efficacy Measures ◽  
Efficacy Parameters ◽  
Necrosis Factor

Etanercept is a soluble tumour necrosis factor receptor fusion protein which is approved for the treatment of plaque psoriasis at the dose of either 25mg twice weekly (BIW) or, for the initial 12 weeks, 50mg BIW. Alternative dosing regimens have not been evaluated in psoriasis. In this study, we compare the efficacy and tolerability of two etanercept dosing regimens - 50mg BIW and 100mg once weekly (OW) - for 12 weeks in 108 patients with moderate-to-severe recalcitrant psoriasis. Efficacy measures included Psoriasis Area and Severity Index (PASI), severity of pruritus recorded on a visual analogue scale (VAS) and the influence on quality of life assessed by means of Dermatology Life Quality Index (DLQI). Both etanercept regimens caused a significant change in all the efficacy parameters after 4 weeks and 12 weeks, at a comparable rate. At week 12, a PASI improvement of at least 50% from baseline (PASI 50) was achieved by 74% of patients treated with 50mg BIW and 78% of patients treated with 100mg OW. A PASI 75 response was obtained in 54% and 50% of patients treated with 50mg BIW and 100mg OW, respectively. Treatment was well tolerated with similar type and frequency of adverse events between the two groups.

scholarly journals Scalp Psoriasis and Biologic Agents: A Review

2021 ◽  
pp. 1-10
Author(s):  
Ilias Papadimitriou ◽  
Katerina Bakirtzi ◽  
Alexander Katoulis ◽  
Dimitrios Ioannides
Keyword(s):  
Quality Of Life ◽  
Plaque Psoriasis ◽  
Psychological Impact ◽  
Life Quality ◽  
Severity Index ◽  
Scalp Psoriasis ◽  
Significant Regression ◽  
Term Maintenance

Scalp-localized psoriasis is common among patients affected with plaque psoriasis, rendering its treatment exceedingly difficult. Furthermore, the symptoms caused by the disease like scaling, erythema, and pruritus, among others, pose a major psychological impact and a significant regression in the quality of life of the affected patients. Biologics have proved their efficacy in assuaging the symptoms, in terms of Psoriasis Area and Severity Index (PASI) reduction, and offering optimum quality of life, by decreasing the Dermatology Life Quality Index (DLQI) in the patients suffering from plaque psoriasis. Herein, we sought to evaluate the efficacy of biologics and small molecules in controlling the symptoms and their ability to offer long-term maintenance in the disease activity.

scholarly journals Reporting of Quality of Life in Clinical Trials of Biologics for Plaque Psoriasis: A Systematic Review

2018 ◽  
Vol 2 (5) ◽  
Author(s):  
Giselle Prado ◽  
Anna J Nichols ◽  
Mercedes Florez-White ◽  
Francisco Kerdel
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Clinical Trials ◽  
Plaque Psoriasis ◽  
Dermatology Life Quality Index ◽  
Quality Index ◽  
Life Quality ◽  
Risk Of Bias ◽  
The Mean

Background: Psoriasis is a chronic remitting and relapsing skin disease. For many patients, improved quality of life (QoL) is as important as clinical improvement of lesions.Objective: To review reporting of Dermatology Life Quality Index (DLQI) in randomized controlled trials (RCTs) of biologics for adult patients with plaque psoriasis.Methods: A systematic review was conducted in 4 databases for RCTs that measured DLQI at baseline and endpoint. A data collection form was created for collecting study variables. Risk of bias was assessed using the Cochrane risk of bias tool.Results: Thirty-four RCTs enrolling 16,784 patients were included. Complete baseline and final mean DLQI data was retrieved for 24 studies (70.6%). The mean DLQI at baseline was reported in 79.4% of RCTs. The median at baseline was reported in 14.7% of RCTs. The mean DLQI at endpoint was reported in 23.5% of RCTs and the median DLQI at endpoint was reported in 5.9% of RCTs. The mean change in DLQI was reported in 64.7% of RCTs.Conclusions: DLQI was measured in most clinical trials assessing the efficacy of biologics for psoriasis. Studies did not adhere to uniform standards in publishing results, making analysis of the impact on DLQI challenging.Key Words: plaque psoriasis, quality of life, Dermatology Life Quality Index, Systematic Review, biologic therapy

The evaluation of the effectiveness of structural resonance therapy in the patients with lupus erythematosus and comorbid pathology of the gastrointestinal tract

2016 ◽  
Vol 15 (6) ◽  
pp. 305-308
Author(s):  
Roman Nikolaevich Levshin ◽  
K. V Kotenko ◽  
L. S Kruglova ◽  
N. B Korchazhkina
Keyword(s):  
Gastrointestinal Tract ◽  
Lupus Erythematosus ◽  
Dermatology Life Quality Index ◽  
Life Quality ◽  
Severity Index ◽  
Combined Approach ◽  
General Health Status ◽  
Combined Application ◽  
Medicinal Treatment

The authors report the results obtained during the combined application of various regimens of structural resonance therapy (SRT) for the treatment of 40 patients presenting with lupus erythematosus (LE) and comorbid pathology of the gastrointestinal tract. The use of this approach in the combination with the standard medicinal treatment made it possible to achieve clinical remission of the disease and to significantly improve the skin process in 100% of the patients as appears from the data on dynamics of the severity index of the cutaneous process. Simultaneously, the general health status of the patients was considerably improved. It is concluded that the proposed combined approach markedly increases the patients’ quality of life being responsible for a 87% reduction of the quality of the dermatology life quality index which allows to recommend this method for the wide application in the clinical practice for the management of the patients with the widespread forms of lupus erythematosus and comorbid pathology of the gastrointestinal tract.

Psoriatic Nail Disease: Quality of Life and Treatment

2009 ◽  
Vol 13 (5_suppl) ◽  
pp. S102-S106 ◽  
Author(s):  
Aditya K. Gupta ◽  
Elizabeth A. Cooper
Keyword(s):  
Quality Of Life ◽  
Psoriatic Arthritis ◽  
Plaque Psoriasis ◽  
Large Scale ◽  
Severity Index ◽  
Biologic Therapies ◽  
Nail Psoriasis ◽  
Psoriatic Nail Disease

Nail psoriasis is common among patients with plaque psoriasis or psoriatic arthritis and has a detrimental effect on quality of life. However, there are currently no standardized therapeutic regimens for nail psoriasis. Traditional treatments for nail psoriasis, which include topical, intralesional, and oral therapies, may be time-consuming, painful, or unsafe when administered long term. Biologic therapies have demonstrated efficacy for plaque psoriasis and psoriatic arthritis; these therapies may be particularly promising for the treatment of nail psoriasis as both groups of patients have an elevated incidence of nail dystrophy. The biologic therapies adalimumab, alefacept, efalizumab, etanercept, and infliximab have demonstrated clinically important nail psoriasis improvements using the Nail Psoriasis Severity Index, a helpful tool that, upon validation, will allow comparison across treatments and trials. Large-scale, long-term trials using standardized outcome measures are needed to further evaluate biologic therapies for the treatment of nail psoriasis.

Adalimumab in the Treatment of Psoriasis: Pooled Efficacy and Safety Results from Three Pivotal Studies

2009 ◽  
Vol 13 (5_suppl) ◽  
pp. S58-S66 ◽  
Author(s):  
Kim Papp ◽  
Martin Okun ◽  
Ronald Vender
Keyword(s):  
Clinical Trials ◽  
Human Monoclonal Antibody ◽  
Severity Index ◽  
Efficacy And Safety ◽  
Controlled Clinical Trials ◽  
Psoriasis Area Severity Index ◽  
Treatment Groups ◽  
Efficacy Measure ◽  
Efficacy Measures ◽  
Necrosis Factor

Background: Adalimumab, a fully human monoclonal antibody, binds to and neutralizes tumor necrosis factor. Objective: To provide an integrated review of efficacy and safety from adalimumab clinical trials in psoriasis. Methods: Pooled analyses were conducted of three placebo-controlled clinical trials of adalimumab (40 mg every other week) in psoriasis patients. The primary efficacy measure was the Psoriasis Area Severity Index (PASI). The Physician's Global Assessment (PGA) was also assessed. Results: At Week 16, mean percentage PASI improvement was 78.3% for adalimumab-treated patients versus 15.1% for placebo-treated patients. A PGA of “Clear” or “Minimal” was achieved in 63.4% of adalimumab-treated patients versus 5.1% of placebo-treated patients. The response to adalimumab was rapid, with significant improvements for adalimumab-treated patients in most efficacy measures by Week 4. Adverse event incidence was similar between treatment groups and consistent with adalimumab safety profiles in other indications. Conclusion: Adalimumab improved psoriasis and was generally safe and well-tolerated.

The Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index (B-SNIPI): A Novel Index to Measure All Non-plaque Psoriasis Subsets

2014 ◽  
Vol 41 (6) ◽  
pp. 1230-1232 ◽  
Author(s):  
Mital Patel ◽  
Stephanie W. Liu ◽  
Abrar Qureshi ◽  
Joseph F. Merola
Keyword(s):  
Plaque Psoriasis ◽  
Composite Index ◽  
Objective Measure ◽  
Severity Index ◽  
Chronic Inflammatory Disease ◽  
Response To Treatment ◽  
Psoriatic Skin ◽  
Patient Reported ◽  
Significant Impairment

Psoriasis is a chronic inflammatory disease that encompasses a large spectrum of clinically distinct subtypes. Although chronic plaque psoriasis is reported as the most common form of psoriatic skin disease, there is growing evidence that other variants including scalp, nail, inverse, and palmoplantar psoriasis are prevalent, undertreated, and associated with significant impairment in quality of life. Currently, the Psoriasis Area and Severity Index (PASI) is the standard to assess psoriasis severity as well as response to treatment; however, the PASI has several limitations. In response to this need and as a complementary objective measure to the PASI, we created the Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index (B-SNIPI), based on patient-surveyed, patient-reported outcomes equally weighted with physician assessment of disease activity. Herein we summarize the B-SNIPI as presented at the 2013 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

scholarly journals Correlation of Disease Activity and Quality of Life of Patients with Psoriasis after Narrow-band Ultraviolet B Therapy

Folia Medica ◽  
2020 ◽  
Vol 62 (1) ◽  
pp. 89-93
Author(s):  
Lyubomir A. Dourmishev ◽  
Karolina Lyubomirova
Keyword(s):  
Quality Of Life ◽  
Narrow Band ◽  
Life Quality ◽  
Clinical Effectiveness ◽  
Symptom Assessment ◽  
Severity Index ◽  
Ultraviolet B ◽  
Effective Treatment Option ◽  
Pasi Score

Introduction: Treatment with ultraviolet light is a well-established and effective treatment option for mild to moderate psoriasis. The aims of the study were to measure the psoriasis area and severity index (PASI) reduction after narrow-band ultraviolet B (NB UVB) therapy, to evaluate the quality of life before and after treatment using the dermatology life quality index (DLQI), and to compare the clinical effectiveness with quality of life improvement.   Material and methods: Twenty two patients (13 male and 9 female patients), aged between 21 to 70 years (mean age 40±14.65 years) were enrolled in the study. NB UVB treatment was performed with 10 to 25 (mean 18.5; SD 3.39) procedures with cumulative doses of 5 to 19.4 J/cm2. The baseline median PASI score was 20.027 which decreased after therapy to 11.11. More than PASI 50% reduction was achieved in 40.91% of the patients after at least 6 weeks of treatment and the results are highly statistically significant. Quality of life (QoL) assessed using DLQI was found moderately affected by disease pretreatment. NB UVB therapy significantly increased DLQI score in spectrum of ‘symptoms and feelings’ and ‘treatment’.   Discussion: The PASI score reduction that we observed after NB-UVB therapy is consistent with the results reported by other authors. Baseline DLQI scores were indicative of moderate QoL impairments associated with disease. At the same time, the reduction of the DLQI index corresponding to improved QoL correlated with the objective clinical symptom assessment.    Conclusion: Our data suggest that DLQI and PASI indexes are important complementary methods for comprehensive health assessment of patients with psoriasis. 

scholarly journals An Observational Study to Evaluate Quality of Life in Patients with Melasma in A Tertiary Level Hospital of Pokhara

2021 ◽  
Vol 19 (1) ◽  
pp. 37-41
Author(s):  
Prajwal Pudasaini ◽  
Saraswoti Neupane
Keyword(s):  
Quality Of Life ◽  
Age Of Onset ◽  
Life Quality ◽  
Sun Exposure ◽  
Severity Index ◽  
Cross Sectional ◽  
Medical College ◽  
The Mean ◽  
Hormonal Therapies

Introduction: Melasma is an acquired hyper melanosis that becomes more pronounced after sun exposure. Centro facial which is the commonest pattern followed by Malar and Mandibular are three clinical patterns of Melasma. Genetic influences, exposure to UV radiation, pregnancy, hormonal therapies, contribute to the pathogenesis of melasma. Melasma may considerably have significant effect on quality of life of patients.   Objectives: The present study was conducted to evaluate the effects of melasma in quality of life (QoL) in the form of DLQI (Dermatology Life Quality Index) and severity of melasma according to Melasma Area and Severity Index (MASI).   Materials and Methods: This is a hospital based cross-sectional prospective study conducted in 193 Melasma patients in the Department of Dermatology, Venereology and Leprology, Gandaki Medical College and Teaching Hospital, Pokhara from November 2018 to November 2019. MASI score was calculated and the patients were provided with a Nepali version of DLQI to fill up.   Results: This study included 193 patients. Mean age of patients with melasma was 29.4 ± 8.5 years with maximum reported age of 59 years. The Mean age of onset of disease was 26.5 years. The Mean age of onset of disease had little impact on DLQI. The mean DLQI score was 10.9 ± 5.9, thus indicating “very large effect on patient’s life”. The mean MASI score was 6.6 ± 5.2. It was found that there was no correlation between severity of disease and DLQI scores (p=0.317) Conclusion: Melasma commonly affected females during second and third decades of life. It had a very large effect on patient’s life as assessed by DLQI.    

The Effect of Psoriasis on Patients' Quality of Life and Improvements Associated with Alefacept Therapy

2004 ◽  
Vol 8 (2_suppl) ◽  
pp. 20-25
Author(s):  
Alan Menter
Keyword(s):  
Quality Of Life ◽  
Unmet Need ◽  
Life Quality ◽  
Severity Index ◽  
Biologic Agent ◽  
Number Of Patients ◽  
Negative Effect ◽  
Clinical Measures

Patients with psoriasis may experience impaired psychosocial mental status regardless of their objectively defined disease severity. The objective clinical measures of disease that are commonly used to evaluate a patient's psoriasis fail to take into account the effect of psoriasis on patients' quality of life (QOL). As a result, a significant number of patients are dissatisfied with conventional treatments and are searching for new options. A high unmet need for effective and safe long-term therapies that can also improve patients' QOL exists in psoriasis. Alefacept, a selective biologic agent specifically designed for the treatment of psoriasis, provides improvement in both the physical (as measured by the Psoriasis Area and Severity Index) and mental (as measured by the Dermatology Life Quality Index) aspects of the disease. Additionally, alefacept is extremely well tolerated, with no negative effect on QOL, and the improvement in QOL is maintained off-treatment, which is consistent with its remittive effects on the disease. Alefacept helps fulfill the needs of psoriasis patients by providing efficacy, safety, off-treatment remissions, and improvement in QOL.

Sign in / Sign up

Export Citation Format

Share Document